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ABSTRACT
Introduction:

Hepatitis C virus (HCV) is one of the most significant public health
problems currently facing the U.S., especially in West Virginia. If it is
undetected and left untreated, the likelihood of sustaining a treatment
response decreases. While early identification has been identified as a
critical focus in trying to obtain better health outcomes, new drug
treatments appear promising, although somewhat expensive. West
Virginia, a predominantly rural state, is beginning to face a mounting
financial crisis due to HCV.
Purpose of the Study: The purpose of this study was to examine the
effects of early identification and treatment for patients infected with HCV
given the financial restraints in the healthcare delivery in the United States
and in particular in West Virginia.
Methodology: The methodology for this qualitative study was a literature
review. Seven electronic databases were utilized with a total of 50 scholarly
articles being referenced for this research. Additionally, it was performed a
semi-structured interview with an Infectious Disease physician.
Results: The literature review examined several studies that evaluated
acute and chronic HCV identification process and implications for this
population. Also, the semi-structured interview revealed more insight into
HCV identification and treatment. The results demonstrated potential to
increasing QALYs along with highlighting restrictions of current payment
for procedures.
Discussion/Conclusion: The results of the literature review did suggest
that early intervention programs are needed to decrease the incidence and
prevalence of HCV. Several practical implications included the possibility
of obtaining funding for early intervention programs through grants and
the modification of legislation to benefit vulnerable populations. Improving
testing, simplifying screening, and data collection through enhanced
surveillance reporting, along with an expanded specialized clinical
workforce would be of benefit and represent some cost savings.
Research Purposes:
The research goal was to analyze the earlier identification processes
associated with HCV treatment to determine if decreased incidence and
prevalence of the disease could be obtained through early identification
programs.
Hypothesis:
The hypothesis was to determine if preventable health complications
could be recognized through offering affordable alternatives such as
needle exchange programs.

METHODS
The methodology for this study consisted of a qualitative literature
review complemented with a semi-structured interview. Research
articles and peer-reviewed literature were located using Marshall
University’s EbscoHost, CINAHL, ProQuest, and PubMed research
databases.
A professional presentation was also utilized as a source of research
for vital data that contributed to the literature review. The information
gained from these articles, websites, and presentation were used as the
sources of primary and secondary materials.

BACKGROUND

RESULTS

• As many as one-third of US Citizens are living at or below 200%
of the federal poverty level, have struggled to afford the even
modest prescription drug.

Early Identification of Hepatitis C Virus in USA and West Virginia
• 68% of newly diagnosed cases of HCV were due to Injectable Drug Users
(IDUs). Although approximately 33% of US Citizens 18 to 30 years old
were infected with HCV; older former IDU’s typically had a much higher
prevalence (about 70%-90%) of HCV, reflecting the increased risk of
continued injection drug use (HHS, 2017)
• West Virginia consistently has reported over four times the national
average of acute HCV cases, 3.4 per 100,000 in West Virginia compared to
0.8 in the U.S (CDC, 201b)

• Poverty in West Virginia is widespread: in 2013, the state ranked
41st in percentage of people who had incomes below the
poverty line of $23,834 for a family of four (Center for American
Progress, 2018), a situation mostly unchanged for over 50 years
(Gabriel, 2014).
• The HCV outbreak as an economical and societal issue, is
rooted in poverty (Fischer, 2015).
• HCV remains a mostly undetected disease due to its lack of
symptoms until it reaches its later stages.

Hospitalization Costs Associated with Hepatitis C Virus+
• Inpatient acute hospitalization due to HCV has shown that diagnosis of
HCV more than tripled from 20,963 in 2004-2005 to 64,867 in 2010-2011.
• The nationwide rate of those admissions per 100,000 people increased
from 4.76 to 13.81 per 100,000 people, a relative percent change of 190%
in 2004-2005 compared to 2010-2011.
• When combined the total nationwide charges or hospitalization with HCV
as the principal diagnosis increased from $0.9 billion during 2004-2005 to
$3.5 billion during 2010-2011.

• There is currently no vaccine for hepatitis C.
• Very Expensive new Medications are the current form of
treatment (WHO, 2015).
•

The quality-adjusted life year or Quality-Adjusted-Life-Year
(QALY) is a generic measure of disease burden, including both
the quality and the quantity of life lived. It is used in economic
evaluation to assess the value for money of medical
interventions. One QALY equates to one year in perfect health.

Payment issues
• Treatment for all HCV-infected patients has proved to be a formidable
hurdle; e.g., in 33 state Medicaid programs, the only patients who
qualified for HCV treatments were the sickest – those whose infection has
progressed to severe liver disease (Canary, Klevens, and Holmsberg,
2015).
• Medicare has a less restrictive standard than Medicaid and commercial
payers and requires insurance companies that administer part D to cover
medically necessary drugs approved by the FDA for recommended
treatments.

RESULTS
Table 1: Reported cases of acute HCV, West Virginia and the
United States, 2011-2015 (per 100,000)
Source: CDC, 2015
Rate 2011 Rate 2012 Rate 2013 Rate 2014 Rate 2015
West
Virginia
United
States

2.5
0.4

3.0
0.6

3.1

3.4

0.7

3.4

0.7

West Virginia Responses to Hepatitis C Virus Epidemic
• West Virginia has implemented Syringe Access Programs (SAPs).
• These programs attempt to reduce the risk of spreading hepatitis by
providing the public access to sterile syringe and needles to discourage
the reuse and sharing of injection devises between drug partners during
drug activity.

0.8

Table 2: Trends in Rates and Costs of Hospitalization in Adults
in the Nationwide Inpatient Sample for HCV or advanced Liver
Disease, 2004-2011
Source: Xu, Tong, and Leidner (2014)
Principal Diagnosis: Hepatitis C
Infection

2004-05

2010-11

Number of Hospitalization

20,963

64,867

Rate per 100,000 people

4.76

13.81

Average per hospitalization charge

$42,415

$53,626

•

On the other hand, in many states, including West Virginia, medications such
as Harvoni requires prior authorization. The criteria for approval is long and
specific. However, the approval criteria defeat the purpose of early intervention.

CONCLUSIONS AND PRACTICAL IMPLICATIONS
•
•
•
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•

Screening by birth cohort (Baby Boomers) and dangerous behavior (especially
intravenous drug use) are critical approaches.
Better treatment options in the form of all oral medications have been made
available recently.
While these medications have been shown to be useful on a societal basis, they
are quite costly (and therefore difficult to obtain) on an individual basis.
Improving testing and simplifying screening and data collection through
enhanced surveillance reporting systems to adapt to changing health
information technologies
One practical implication is the need for support from the local community, state
and federal governments, and healthcare providers to comply with strict
adherence to safe and effective standards of care.

